Myeloproliferative Neoplasms (MPN) Study

What we are studying

We are attempting to better understand the causes of myeloproliferative neoplasms (MPN) and to develop improved methods for the diagnosis and treatment of these diseases. These syndromes carry a high risk of developing leukemia. It is important to continue learning more about these blood cancers and to learn more about the effectiveness and potential side effects of various treatments. It is our belief that further basic knowledge about these cancer cells, as well as the effects of treatment, will lead to the improvement of current therapies and the development of entirely new treatments for these diseases. We are hoping to determine if a number of laboratory tests (biomarkers) will allow us to predict if future patients will respond to the treatment you are receiving.

Who we are studying

Men and Women
Races:
- White
- African American
- Asian
- American Indian or Alaska Native
- Native Hawaiian or Pacific Islander
- Other
All Ethnicities
Ages 18+

Eligibility Criteria

Patients diagnosed with the following myeloproliferative neoplasms including:
- Polycythemia vera (PV)
- Primary myelofibrosis (PMF)
- And essential thrombocythemia (ET)

What is involved

Blood and bone marrow samples at the following times: at diagnosis or before starting treatment; time points during treatment; if/when the disease responds to treatment
If/When the disease comes back
Toenail clippings obtained at diagnosis or before starting treatment